Skip to main content
SpringerLink
Log in

Gender Differences in Implantable Cardioverter-Defibrillator Utilization for Primary Prevention of Sudden Cardiac Death

  • Arrhythmia (R Kabra, Section Editor)
  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Abstract

Purpose of review

Implantable cardioverter-defibrillator (ICD) implantation is a guideline-recommended indication for primary prevention of sudden cardiac death (SCD) in high-risk patients. ICD implantation is lower in women than in men, a difference that has persisted over the last two decades. The goal of this review is to explore potential factors in under- utilization of ICDs in women and to provide information on gender differences in mortality benefit of ICDs.

Recent findings

Epidemiological evidence shows that women with cardiovascular disease tend to present at an older age, have more non-ischemic cardiomyopathy, and develop fewer ventricular arrhythmias than men. Significant gender differences in participants of ICD clinical trials challenge the applicability of mortality benefit of ICDs in women. Studies of cardiac resynchronization therapy (CRT) devices have shown improved survival in women over men, a fact that is not reflected in the number of CRTs implanted in women.

Summary

A gender gap in the implantation of ICDs for primary prevention of SCD continues to exist. Understanding of differences in epidemiology and physiology between women and men is an important step in providing appropriate device therapy to patients at risk of SCD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Stecker EC, Reinier K, Marijon E, Narayanan K, Teodorescu C, Uy-Evanado A, et al. Public health burden of sudden cardiac death in the United States. Circ Arrhythm Electrophysiol. 2014;7(2):212–7.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann Intern Med. 1993;119(12):1187–97.

    Article  CAS  PubMed  Google Scholar 

  3. •• Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS Guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018;72(14):e91-e220. Latest guidelines on criteria for implantation of ICD and CRT.

  4. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335(26):1933–40.

    Article  CAS  PubMed  Google Scholar 

  5. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877–83.

    Article  PubMed  Google Scholar 

  6. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151–8.

    Article  CAS  PubMed  Google Scholar 

  7. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–37.

    Article  CAS  PubMed  Google Scholar 

  8. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341(25):1882–90.

    Article  CAS  PubMed  Google Scholar 

  9. Gregoratos G, Cheitlin MD, Conill A, Epstein AE, Fellows C, Ferguson TB Jr, et al. ACC/AHA Guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: executive summary –a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). Circulation. 1998;97(13):1325–35.

    Article  CAS  PubMed  Google Scholar 

  10. Ghanbari H, Dalloul G, Hasan R, Daccarett M, Saba S, David S, et al. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials. Arch Intern Med. 2009;169(16):1500–6.

    Article  PubMed  Google Scholar 

  11. Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375(13):1221–30.

    Article  PubMed  Google Scholar 

  12. Kannel WB, Wilson PW, D’Agostino RB, Cobb J. Sudden coronary death in women. Am Heart J. 1998;136(2):205–12.

    Article  CAS  PubMed  Google Scholar 

  13. Bogle BM, Ning H, Mehrotra S, Goldberger JJ, Lloyd-Jones DM. Lifetime risk for sudden cardiac death in the community. J Am Heart Assoc. 2016;5(7).

  14. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation. 2001;104(18):2158–63.

    Article  CAS  PubMed  Google Scholar 

  15. Myerburg RJ, Junttila MJ. Sudden cardiac death caused by coronary heart disease. Circulation. 2012;125(8):1043–52.

    Article  PubMed  Google Scholar 

  16. Russo AM, Stamato NJ, Lehmann MH, Hafley GE, Lee KL, Pieper K, et al. Influence of gender on arrhythmia characteristics and outcome in the Multicenter UnSustained Tachycardia Trial. J Cardiovasc Electrophysiol. 2004;15(9):993–8.

    Article  PubMed  Google Scholar 

  17. •• Zaman S, Deshmukh T, Aslam A, Martin C, Kovoor P. Sex differences in electrophysiology, ventricular tachyarrhythmia, cardiac arrest and sudden cardiac death following acute myocardial infarction. Heart Lung Circ. 2020;29(7):1025–31. This study evaluated gender differences in inducibility of ventricular arrhythmias with electrophysiology studies within 40 days of percutaneous intervention for ST elevation myocardial infarction.

    Article  PubMed  Google Scholar 

  18. Lampert R, McPherson CA, Clancy JF, Caulin-Glaser TL, Rosenfeld LE, Batsford WP. Gender differences in ventricular arrhythmia recurrence in patients with coronary artery disease and implantable cardioverter-defibrillators. J Am Coll Cardiol. 2004;43(12):2293–9.

    Article  PubMed  Google Scholar 

  19. Gauri AJ, Davis A, Hong T, Burke MC, Knight BP. Disparities in the use of primary prevention and defibrillator therapy among blacks and women. Am J Med. 2006;119(2):167.e17-21.

    Article  Google Scholar 

  20. Curtis LH, Al-Khatib SM, Shea AM, Hammill BG, Hernandez AF, Schulman KA. Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. JAMA. 2007;298(13):1517–24.

    Article  CAS  PubMed  Google Scholar 

  21. Hernandez AF, Fonarow GC, Liang L, Al-Khatib SM, Curtis LH, LaBresh KA, et al. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA. 2007;298(13):1525–32.

    Article  CAS  PubMed  Google Scholar 

  22. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline update for implantation of cardiac pacemakers and antiarrhythmia devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;51(21):e1-62.

    Article  PubMed  Google Scholar 

  23. Al-Khatib SM, Hellkamp AS, Hernandez AF, Fonarow GC, Thomas KL, Al-Khalidi HR, et al. Trends in use of implantable cardioverter-defibrillator therapy among patients hospitalized for heart failure: have the previously observed sex and racial disparities changed over time? Circulation. 2012;125(9):1094–101.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Johnson AE, Adhikari S, Althouse AD, Thoma F, Marroquin OC, Koscumb S, et al. Persistent sex disparities in implantable cardioverter-defibrillator therapy. Pacing Clin Electrophysiol. 2018;41(9):1150–7.

    Article  PubMed  Google Scholar 

  25. MacFadden DR, Tu JV, Chong A, Austin PC, Lee DS. Evaluating sex differences in population-based utilization of implantable cardioverter-defibrillators: role of cardiac conditions and noncardiac comorbidities. Heart Rhythm. 2009;6(9):1289–96.

    Article  PubMed  Google Scholar 

  26. Sticherling C, Arendacka B, Svendsen JH, Wijers S, Friede T, Stockinger J, et al. Sex differences in outcomes of primary prevention implantable cardioverter-defibrillator therapy: combined registry data from eleven European countries. Europace. 2018;20(6):963–70.

    Article  PubMed  Google Scholar 

  27. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361(14):1329–38.

    Article  PubMed  Google Scholar 

  28. Dhruva SS, Redberg RF. Variations between clinical trial participants and Medicare beneficiaries in evidence used for Medicare national coverage decisions. Arch Intern Med. 2008;168(2):136–40.

    Article  PubMed  Google Scholar 

  29. Russo AM, Poole JE, Mark DB, Anderson J, Hellkamp AS, Lee KL, et al. Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial. J Cardiovasc Electrophysiol. 2008;19(7):720–4.

    Article  PubMed  Google Scholar 

  30. Rho RW, Patton KK, Poole JE, Cleland JG, Shadman R, Anand I, et al. Important differences in mode of death between men and women with heart failure who would qualify for a primary prevention implantable cardioverter-defibrillator. Circulation. 2012;126(20):2402–7.

    Article  PubMed  Google Scholar 

  31. Zareba W, Moss AJ, Jackson Hall W, Wilber DJ, Ruskin JN, McNitt S, et al. Clinical course and implantable cardioverter defibrillator therapy in postinfarction women with severe left ventricular dysfunction. J Cardiovasc Electrophysiol. 2005;16(12):1265–70.

    Article  PubMed  Google Scholar 

  32. Albert CM, Quigg R, Saba S, Estes NA 3rd, Shaechter A, Subacius H, et al. Sex differences in outcome after implantable cardioverter defibrillator implantation in nonischemic cardiomyopathy. Am Heart J. 2008;156(2):367–72.

    Article  PubMed  Google Scholar 

  33. Santangeli P, Pelargonio G, Dello Russo A, Casella M, Bisceglia C, Bartoletti S, et al. Gender differences in clinical outcome and primary prevention defibrillator benefit in patients with severe left ventricular dysfunction: a systematic review and meta-analysis. Heart Rhythm. 2010;7(7):876–82.

    Article  PubMed  Google Scholar 

  34. Arana-Rueda E, Jáuregui B, Frutos-López M, Acosta J, Sánchez-Brotons JA, García-Riesco L, et al. Long-term survival after implantable cardiac defibrillator therapy according to sex: a propensity matched study. J Womens Health (Larchmt). 2020.

  35. Zeitler EP, Hellkamp AS, Schulte PJ, Fonarow GC, Hernandez AF, Peterson ED, et al. Comparative effectiveness of implantable cardioverter defibrillators for primary prevention in women. Circ Heart Fail. 2016;9(1):e002630.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Wilcox JE, Fonarow GC, Zhang Y, Albert NM, Curtis AB, Gheorghiade M, et al. Clinical effectiveness of cardiac resynchronization and implantable cardioverter-defibrillator therapy in men and women with heart failure: findings from IMPROVE HF. Circ Heart Fail. 2014;7(1):146–53.

    Article  PubMed  Google Scholar 

  37. •• Haukilahti MAE, Holmstrom L, Vahatalo J, Kentta T, Tikkanen J, Pakanen L, et al. Sudden cardiac death in women. Circulation. 2019;139(8):1012–21. This study analyzed pathophysiology differences between men and women who died of sudden death using clinical and autopsy data.

    Article  PubMed  Google Scholar 

  38. Spain DM, Bradess VA, Mohr C. Coronary atherosclerosis as a cause of unexpected and unexplained death: an autopsy study from 1949–1959. JAMA. 1960;174(4):384–8.

    Article  CAS  PubMed  Google Scholar 

  39. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292(23):2874–9.

    Article  CAS  PubMed  Google Scholar 

  40. Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, et al. Declining risk of sudden death in heart failure. N Engl J Med. 2017;377(1):41–51.

    Article  PubMed  Google Scholar 

  41. •• McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. Major advancement in medical management of heart failure with reduction in mortality.

    Article  CAS  PubMed  Google Scholar 

  42. Docherty KF, Vaduganathan M, Solomon SD, McMurray JJV. Sacubitril/Valsartan: Neprilysin inhibition 5 years after PARADIGM-HF. JACC Heart Fail. 2020;8(10):800–10. (Major advancement in medical management of heart failure with reduction in mortality.).

    Article  PubMed  Google Scholar 

  43. Al-Khatib SM, Fonarow GC, Joglar JA, Inoue LYT, Mark DB, Lee KL, et al. Primary prevention implantable cardioverter defibrillators in patients with nonischemic cardiomyopathy: a meta-analysis. JAMA Cardiol. 2017;2(6):685–8.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Alba AC, Foroutan F, Duero Posada J, Battioni L, Schofield T, Alhussein M, et al. Implantable cardiac defibrillator and mortality in non-ischaemic cardiomyopathy: an updated meta-analysis. Heart. 2018;104(3):230–6.

    Article  PubMed  Google Scholar 

  45. Romero J, Chaudhary R, Garg J, Lupercio F, Shah N, Gupta R, et al. Role of implantable cardioverter defibrillator in non-ischemic cardiomyopathy: a systematic review and meta-analysis of prospective randomized clinical trials. J Interv Card Electrophysiol. 2017;49(3):263–70.

    Article  PubMed  Google Scholar 

  46. Elming MB, Nielsen JC, Haarbo J, Videbæk L, Korup E, Signorovitch J, et al. Age and outcomes of primary prevention implantable cardioverter-defibrillators in patients with nonischemic systolic heart failure. Circulation. 2017;136(19):1772–80.

    Article  PubMed  Google Scholar 

  47. Frazier CG, Alexander KP, Newby LK, Anderson S, Iverson E, Packer M, et al. Associations of gender and etiology with outcomes in heart failure with systolic dysfunction: a pooled analysis of 5 randomized control trials. J Am Coll Cardiol. 2007;49(13):1450–8.

    Article  PubMed  Google Scholar 

  48. Peterson PN, Daugherty SL, Wang Y, Vidaillet HJ, Heidenreich PA, Curtis JP, et al. Gender differences in procedure-related adverse events in patients receiving implantable cardioverter-defibrillator therapy. Circulation. 2009;119(8):1078–84.

    Article  PubMed  Google Scholar 

  49. Russo AM, Daugherty SL, Masoudi FA, Wang Y, Curtis J, Lampert R. Gender and outcomes after primary prevention implantable cardioverter-defibrillator implantation: Findings from the National Cardiovascular Data Registry (NCDR). Am Heart J. 2015;170(2):330–8.

    Article  PubMed  PubMed Central  Google Scholar 

  50. •• Padala SK, Gunda S, Li S, Sharma PS, Koneru JN, Varosy PD, et al. A risk score model for predicting intraprocedural cardiac injury during implantable cardioverter defibrillator implantation: insights from the National Cardiovascular Data Registry. J Cardiovasc Electrophysiol. 2019;30(2):212–20. Evaluation using registry data of factors contributing to intra-procedural complications during ICD and CRT implantation.

    Article  PubMed  Google Scholar 

  51. Tracy CM, Epstein AE, Darbar D, DiMarco JP, Dunbar SB, Estes NA 3rd, et al. 2012 ACCF/AHA/HRS focused update of the 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg. 2012;144(6):e127–45.

    Article  PubMed  Google Scholar 

  52. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539–49.

    Article  CAS  PubMed  Google Scholar 

  53. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140–50.

    Article  CAS  PubMed  Google Scholar 

  54. •• Doran B, Mei C, Varosy PD, Kao DP, Saxon LA, Feldman AM, et al. The addition of a defibrillator to resynchronization therapy decreases mortality in patients with nonischemic cardiomyopathy. JACC Heart Fail. 2021;9(6):439–49. This study evaluated mortality benefit with addition of defibrillation to resynchronization therapy.

    Article  PubMed  Google Scholar 

  55. Loring Z, Caños DA, Selzman K, Herz ND, Silverman H, MaCurdy TE, et al. Left bundle branch block predicts better survival in women than men receiving cardiac resynchronization therapy: long-term follow-up of ∼145,000 patients. JACC Heart Fail. 2013;1(3):237–44.

    Article  PubMed  Google Scholar 

  56. Zusterzeel R, Curtis JP, Caños DA, Sanders WE, Selzman KA, Piña IL, et al. Sex-specific mortality risk by QRS morphology and duration in patients receiving CRT: results from the NCDR. J Am Coll Cardiol. 2014;64(9):887–94.

    Article  PubMed  Google Scholar 

  57. Quesada A, Arteaga F, Romero-Villafranca R, Perez-Alvarez L, Martinez-Ferrer J, Alzueta-Rodriguez J, et al. Sex-specific ventricular arrhythmias and mortality in cardiac resynchronization therapy recipients. JACC Clin Electrophysiol. 2020.

  58. •• Beela AS, Duchenne J, Petrescu A, Ünlü S, Penicka M, Aakhus S, et al. Sex-specific difference in outcome after cardiac resynchronization therapy. Eur Heart J Cardiovasc Imaging. 2019;20(5):504–11. This study retrospectively analyzed clinical data in patients with CRT and determined that women had less scar and more dyssynchrony by echocardiogram, resulting in improved response to CRT.

    Article  PubMed  Google Scholar 

  59. de Waard D, Manlucu J, Gillis AM, Sapp J, Bernick J, Doucette S, et al. Cardiac resynchronization in women: a substudy of the resynchronization-defibrillation for ambulatory heart failure trial. JACC Clin Electrophysiol. 2019;5(9):1036–44.

    Article  PubMed  Google Scholar 

  60. Chatterjee NA, Borgquist R, Chang Y, Lewey J, Jackson VA, Singh JP, et al. Increasing sex differences in the use of cardiac resynchronization therapy with or without implantable cardioverter-defibrillator. Eur Heart J. 2017;38(19):1485–94.

    PubMed  PubMed Central  Google Scholar 

  61. Sridhar AR, Yarlagadda V, Parasa S, Reddy YM, Patel D, Lakkireddy D, et al. Cardiac resynchronization therapy: US trends and disparities in utilization and outcomes. Circ Arrhythm Electrophysiol. 2016;9(3):e003108.

    Article  PubMed  Google Scholar 

  62. Costantini O, Hohnloser SH, Kirk MM, Lerman BB, Baker JH 2nd, Sethuraman B, et al. The ABCD (alternans before cardioverter defibrillator) Trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention. J Am Coll Cardiol. 2009;53(6):471–9.

    Article  PubMed  Google Scholar 

  63. Chow T, Kereiakes DJ, Onufer J, Woelfel A, Gursoy S, Peterson BJ, et al. Does microvolt T-wave alternans testing predict ventricular tachyarrhythmias in patients with ischemic cardiomyopathy and prophylactic defibrillators? The MASTER (microvolt T wave alternans testing for risk stratification of post-myocardial infarction patients) Trial. J Am Coll Cardiol. 2008;52(20):1607–15.

    Article  PubMed  Google Scholar 

  64. Gao P, Yee R, Gula L, Krahn AD, Skanes A, Leong-Sit P, et al. Prediction of arrhythmic events in ischemic and dilated cardiomyopathy patients referred for implantable cardiac defibrillator: evaluation of multiple scar quantification measures for late gadolinium enhancement magnetic resonance imaging. Circ Cardiovasc Imaging. 2012;5(4):448–56.

    Article  PubMed  Google Scholar 

  65. Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013;309(9):896–908.

    Article  CAS  PubMed  Google Scholar 

  66. •• Sánchez-Somonte P, Quinto L, Garre P, Zaraket F, Alarcón F, Borràs R, et al. Scar channels in cardiac magnetic resonance to predict appropriate therapies in primary prevention. Heart Rhythm. 2021. Recent study correlating scar mass by LGE-CMR to ventricular arrhythmias in patients with primary prevention ICD.

  67. Loring Z, Strauss DG, Gerstenblith G, Tomaselli GF, Weiss RG, Wu KC. Cardiac MRI scar patterns differ by sex in an implantable cardioverter-defibrillator and cardiac resynchronization therapy cohort. Heart Rhythm. 2013;10(5):659–65.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Kwon DH, Halley CM, Popovic ZB, Carrigan TP, Zysek V, Setser R, et al. Gender differences in survival in patients with severe left ventricular dysfunction despite similar extent of myocardial scar measured on cardiac magnetic resonance. Eur J Heart Fail. 2009;11(10):937–44.

    Article  PubMed  Google Scholar 

  69. Kwon DH, Hachamovitch R, Adeniyi A, Nutter B, Popovic ZB, Wilkoff BL, et al. Myocardial scar burden predicts survival benefit with implantable cardioverter defibrillator implantation in patients with severe ischaemic cardiomyopathy: influence of gender. Heart. 2014;100(3):206–13.

    Article  PubMed  Google Scholar 

  70. Selvanayagam JB, Hartshorne T, Billot L, Grover S, Hillis GS, Jung W, et al. Cardiovascular magnetic resonance-GUIDEd management of mild to moderate left ventricular systolic dysfunction (CMR GUIDE): study protocol for a randomized controlled trial. Ann Noninvasive Electrocardiol. 2017;22(4).

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular Disease, University of Minnesota, 420 Delaware St SE, MMC 508, Room 278 VCRC, Minneapolis, MN, 55455, USA

    Garima Dahiya MD & Jane Chen MD

Authors
  1. Garima Dahiya MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jane Chen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jane Chen MD.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Arrhythmia

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dahiya, G., Chen, J. Gender Differences in Implantable Cardioverter-Defibrillator Utilization for Primary Prevention of Sudden Cardiac Death. Curr Treat Options Cardio Med 23, 75 (2021). https://doi.org/10.1007/s11936-021-00954-x

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11936-021-00954-x

Keywords

Search

Navigation